|Articles|December 2, 2013
Lilly Strategy: Timely, Valued Medicines to Patients
Dr. Jan Lundberg, EVP science and technology and president Lilly Research Labs, Lilly & Co., sits down to discuss the company?s new approach to drug development and its Phase III pipeline.
Advertisement
Dr. Jan Lundberg, EVP science and technology and president Lilly Research Labs, Lilly & Co., sits down to discuss the company’s new approach to drug development and its Phase III pipeline.
For more videos tune in to:
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Organon CEO Kevin Ali to Resign Following Internal Investigation into Nexplanon Sales
2
Study Claims Ozempic Lowers Biological Age
3
Pharmaceutical Executive Daily: Organon CEO Kevin Ali Resigns
4
How will DTC Programs Impact PBMs?
5
